MedTrace Logo

A Study of Perturbation of Human Small Intestinal Colonic Permeability

NCT06033222 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of castor oil versus placebo on intestinal permeability in healthy individuals.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Ricinoleic Acid 750 mg

750 mg administered orally

DIETARY_SUPPLEMENT

Ricinoleic Acid 1500 mg

1500 mg administered orally

DIETARY_SUPPLEMENT

Ricinoleic Acid 3000 mg

3000 mg administered orally

DRUG

Placebo

Contains no active ingredient.

Sponsors & Collaborators

Principal Investigators

  • Michael Camilleri, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2024-05-23
Completion
2024-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06033222 on ClinicalTrials.gov